K
13.58
-3.32 (-19.64%)
| Previous Close | 16.90 |
| Volume | 1,179,251 |
| Price / Sales | 942.67 |
| Price / Book | 5.94 |
| 52 Weeks Range |
| Operating Margin (TTM) | -42,029.54% |
| Diluted EPS (TTM) | -29.16 |
| Quarterly Revenue Growth (YOY) | 557,150.00% |
| Total Debt/Equity (MRQ) | 6.82% |
| Current Ratio (MRQ) | 0.210 |
| Operating Cash Flow (TTM) | -11.67 M |
| Levered Free Cash Flow (TTM) | -6.16 M |
| Return on Assets (TTM) | -85.55% |
| Return on Equity (TTM) | -3,891.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Kazia Therapeutics Limited | Mixed | Bullish |
AIStockmoo Score
-1.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -1.5 |
| Average | -1.00 |
|
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.09% |
| % Held by Institutions | 8.22% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |